TargetBeta
IL11
interleukin 11 · also IL-11, AGIF · Interleukins
2 programs in company-led studies act on IL11, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-IL-11 Monoclonal Antibody 9MW3811rule | Mabwell (Shanghai) Bioscience | phase 2 | 43 running | – | NCIt |
| BI 765423 | Boehringer Ingelheim | phase 2 | 31 running | – | the company's pipeline |
Conditions their studies are in
- Idiopathic Pulmonary Fibrosis, 2 programs
- Cicatrix, 1 program
- Pulmonary Fibrosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Anti-IL-11 Monoclonal Antibody 9MW3811 · Mabwell (Shanghai) Bioscience · phase 2 · NCT07576608
- Mar 11, 2027BI 765423 · Boehringer Ingelheim · phase 2 · NCT07036523
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.